- Excellent performance for Theranostics sales, up
13%
- Further expansion in activity in the United States, with
growth of 17%
- Growth in the Company’s historical IVD activity
- Cash position at December 31, 2021: €7.1 million
Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a
company specializing in in vitro diagnostics of autoimmune diseases
and Theranostics, today reported its 2021 annual revenue and its
cash position at December 31, 2021.
Bertrand de Castelnau, CEO of Theradiag, commented:
“Within a health and economic context that remained hostile, in
2021 Theradiag was able to continue improving its performance
indicators. The solid growth in our revenue objectifies our
successful strategic refocus on our Theranostics business and the
internationalization of our activities in our key geographies.
Henceforth, thanks to the funds raised at the end of last year, we
will concentrate on the deployment of our strategic plan that will
lead to an acceleration in our growth while maintaining strict
control over our costs and healthy management of our cash. Our
ambition is to strengthen our global leadership position on the
biotherapy monitoring market and expand our primary purpose, which
is to accompany the therapy of an ever-growing number of patients
around the world”.
“2021 again demonstrated the resistance of Theradiag’s business
model in a delicate public health context. Now having the means to
achieve our ambitions, in 2022 Theradiag will be able to begin a
new chapter in its history by fully benefiting from its
technological lead on the very high potential biotherapy monitoring
market”, added Pierre Morgon, Chairman of Theradiag’s Board of
Directors.
2021 revenue of €11.1 million, up 6.8%
In thousands of euros
FY 2021
FY 2020
Change
Revenue*
11,125
10,413
+6.8%
of which: Theranostics
5,771
5,120
+12.7%
of which: IVD
5,354
5,293
+1.2%
*Figures currently being audited
Over the year to December 31, 2021, Theradiag recorded revenue
of €11.1 million, versus €10.1 million in 2020, giving growth of
6.8 % in line with the strategic priorities defined by the Company
prior to the Rights Issue implemented at the end of October.
On the strength of the 19 i-Track10 or equivalent analyzers
installed and active around the world, Theranostics activity
recorded another excellent performance with growth of 12.7% in
2021, and now accounts for 52% of Theradiag’s business.
In Vitro Diagnostics (IVD) activity recorded a slight
increase of 1.2% in revenue to €5.3 million. It should be noted
that in 2020, Theradiag generated sales associated with the fight
against Covid of approximately €900 thousand. In 2021, this
activity was marginal.
Globally, Theradiag recorded excellent performances in terms of
exports and in the United States with growth of 25.9% and 17.0%
respectively reflecting the clear success of its overseas
partnerships, such as the one with Veracyte for the marketing of
its tests in the United States. In France, activity was down by
5.9%. This slight decrease can be explained by the market’s
advanced level of maturity and the negative base effect associated
with Covid Ag sales in 2020.
Comfortable cash position with the financing horizon assured
until end-2026
At December 31, 2021, Theradiag had a net cash position of €7.1
million, compared to €1.4 million at June 30, 2021; for the last
year or so, the Company has been able to stabilize its cash
position at around €2 million, excluding capital increase.
Henceforth, following the Rights Issue carried out in October 2021,
the Company has a financing horizon through to 2026 and thus has
medium-term financial autonomy. These additional resources will
allow Theradiag to implement its strategic plan whose key routes
are to:
- Secure the quality and commercial supply of antibodies via the
Humabdiag project developed thanks to the recent partnership with
the University of Tours;
- Accelerate the internationalization of existing activities in
the world’s main healthcare countries, and in particular accelerate
sales in the United States;
- Develop a technological solution to ensure Near Patient
Testing;
- Invest in new therapeutic fields with substantial demand and
strong growth;
- Reposition and revive FIDIS technology, notably in the United
States, as well as the activity covering serums used in quality
control.
Reminder of the Company’s 2021 highlights
- CE marking for the new TRACKER® range i-Tracker® test kits:
Vedolizumab and Ustekinumab kits on originator and biosimilar
molecules;
- Signing of a contract to supply quality control reagents to
Orgentec, a specialist in in vitro diagnostics, notably in
autoimmunity and infectious diseases;
- Participation in Humabdiag, a large-scale research project
undertake with the University of Tours and the University Hospital
of Tours targeting the bioproduction of monoclonal antibodies
notably for Theradiag and the entire biotherapy market;
- €5.33 million Rights Issue;
- Launch of four new i-Tracker® kits and validation of a new
parameter in the United States: Golimumab and Rituximab kits.
Financial calendar:
- 2021 annual results, Monday March 21, 2022
- Annual General Meeting, Thursday May 5, 2022
- H1 2022 revenue, Monday July 18, 2022
- H1 2022 results, Monday September 19, 2022
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2021, the Company posted revenue of €11.1 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
https://www.theradiag.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220130005004/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12
contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent Quentin Massé Tel.: +33 (0)1 44 71 94
94 theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Theradiag (EU:ALTER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Theradiag (EU:ALTER)
Historical Stock Chart
From Apr 2023 to Apr 2024
